Discussion
Asedebart, an experimental treatment designed to ease symptoms in Cushing’s disease and other forms of endogenous Cushing’s syndrome, has been granted orphan drug status in the European Union. That designation, awarded to the Lundbeck therapy by the European Commission, aims to incentivize the development of treatments for rare…